{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:41:33Z","timestamp":1790444493447,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370124"],"award-info":[{"award-number":["82370124"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2022YFA1103300"],"award-info":[{"award-number":["2022YFA1103300"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-54571-w","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T06:50:02Z","timestamp":1732258202000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecules on erythrocytes"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6362-1195","authenticated-orcid":false,"given":"Qi","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyu","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0987-5917","authenticated-orcid":false,"given":"Fan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-6643","authenticated-orcid":false,"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1228-0551","authenticated-orcid":false,"given":"Junling","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2799-7421","authenticated-orcid":false,"given":"Xiaofei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1503-5818","authenticated-orcid":false,"given":"Hsiang-Ying","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"key":"54571_CR1","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1182\/blood.2021010898","volume":"137","author":"C Gurnari","year":"2021","unstructured":"Gurnari, C. & Maciejewski, J. P. How I manage acquired pure red cell aplasia in adults. Blood 137, 2001\u20132009 (2021).","journal-title":"Blood"},{"key":"54571_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1365-2141.2008.07216.x","volume":"142","author":"K Sawada","year":"2008","unstructured":"Sawada, K., Fujishima, N. & Hirokawa, M. Acquired pure red cell aplasia: updated review of treatment. Br. J. Haematol. 142, 505\u2013514 (2008).","journal-title":"Br. J. Haematol."},{"key":"54571_CR3","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1056\/NEJM199404283301704","volume":"330","author":"KE Brown","year":"1994","unstructured":"Brown, K. E. et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N. Engl. J. Med. 330, 1192\u20131196 (1994).","journal-title":"N. Engl. J. Med."},{"key":"54571_CR4","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/j.1365-2141.1994.tb06743.x","volume":"87","author":"N Frickhofen","year":"1994","unstructured":"Frickhofen, N. et al. Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Br. J. Haematol. 87, 818\u2013824 (1994).","journal-title":"Br. J. Haematol."},{"key":"54571_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.autrev.2015.09.005","volume":"15","author":"C Bernard","year":"2016","unstructured":"Bernard, C. et al. Thymoma associated with autoimmune diseases: 85 cases and literature review. Autoimmun. Rev. 15, 82\u201392 (2016).","journal-title":"Autoimmun. Rev."},{"key":"54571_CR6","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1038\/s41375-020-01114-z","volume":"35","author":"C Gurnari","year":"2021","unstructured":"Gurnari, C. et al. Novel invariant features of Good syndrome. Leukemia 35, 1792\u20131796 (2021).","journal-title":"Leukemia"},{"key":"54571_CR7","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1080\/10428194.2017.1339880","volume":"59","author":"SR Sanikommu","year":"2017","unstructured":"Sanikommu, S. R. et al. Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). Leuk. Lymphoma 59, 416\u2013422 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"54571_CR8","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1182\/blood-2016-05-717140","volume":"128","author":"RT Means","year":"2016","unstructured":"Means, R. T. Pure red cell aplasia. Blood 128, 2504\u20132509 (2016).","journal-title":"Blood"},{"key":"54571_CR9","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/j.1875-9114.1996.tb03025.x","volume":"16","author":"DF Thompson","year":"1996","unstructured":"Thompson, D. F. & Gales, M. A. Drug-induced pure red cell aplasia. Pharmacotherapy 16, 1002\u20131008 (1996).","journal-title":"Pharmacotherapy"},{"key":"54571_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0002-9343(89)80833-2","volume":"87","author":"X Mariette","year":"1989","unstructured":"Mariette, X. et al. Rifampicin-induced pure red cell aplasia. Am. J. Med. 87, 459\u2013460 (1989).","journal-title":"Am. J. Med."},{"key":"54571_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood.V65.4.789.789","volume":"65","author":"EN Dessypris","year":"1985","unstructured":"Dessypris, E. N., Redline, S., Harris, J. W. & Krantz, S. B. Diphenylhydantoin-induced pure red cell aplasia. Blood 65, 789\u2013794 (1985).","journal-title":"Blood"},{"key":"54571_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie, B. G. M. et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389, 519\u2013527 (2017).","journal-title":"Lancet"},{"key":"54571_CR13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bjh.15261","volume":"182","author":"EK O\u2019Donnell","year":"2018","unstructured":"O\u2019Donnell, E. K. et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br. J. Haematol. 182, 222\u2013230 (2018).","journal-title":"Br. J. Haematol."},{"key":"54571_CR14","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson, P. G. et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116, 679\u2013686 (2010).","journal-title":"Blood"},{"key":"54571_CR15","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar, S. et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119, 4375\u20134382 (2012).","journal-title":"Blood"},{"key":"54571_CR16","doi-asserted-by":"crossref","unstructured":"Gerecke, C. et al. The Diagnosis and treatment of multiple myeloma. Deutsches \u00c4rzteblatt international (2016).","DOI":"10.3238\/arztebl.2016.0470"},{"key":"54571_CR17","first-page":"4962","volume":"42","author":"Y Chen","year":"2022","unstructured":"Chen, Y., Tao, S., Hu, M. & Fu, C. Efficacy and side effects of low-dose lenalidomide combined with PCD and VAD regimens in the treatment of elderly multiple myeloma. Chin. J. Gerontol. 42, 4962\u20134965 (2022).","journal-title":"Chin. J. Gerontol."},{"key":"54571_CR18","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees, P. M. et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 136, 936\u2013945 (2020).","journal-title":"Blood"},{"key":"54571_CR19","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","volume":"100","author":"PG Richardson","year":"2002","unstructured":"Richardson, P. G. et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100, 3063\u20133067 (2002).","journal-title":"Blood"},{"key":"54571_CR20","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","volume":"187","author":"PAJ Haslett","year":"1998","unstructured":"Haslett, P. A. J., Corral, L. G., Albert, M. & Kaplan, G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med. 187, 1885\u20131892 (1998).","journal-title":"J. Exp. Med."},{"key":"54571_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/blood.V98.1.210","volume":"98","author":"FE Davies","year":"2001","unstructured":"Davies, F. E. et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98, 210\u2013216 (2001).","journal-title":"Blood"},{"key":"54571_CR22","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","volume":"103","author":"R LeBlanc","year":"2004","unstructured":"LeBlanc, R. et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103, 1787\u20131790 (2004).","journal-title":"Blood"},{"key":"54571_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301\u2013305 (2014).","journal-title":"Science"},{"key":"54571_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kr\u00f6nke","year":"2015","unstructured":"Kr\u00f6nke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS. Nature 523, 183\u2013188 (2015).","journal-title":"Nature"},{"key":"54571_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4274\/Tjh.2013.0207","volume":"31","author":"TK Dolai","year":"2014","unstructured":"Dolai, T. K., Dutta, S., Mandal, P. K. & Saha, S. Bhattacharyya M. Lenalidomide-Induced Pure Red Cell Aplasia. Turk. J. Hematol. 31, 99\u2013100 (2014).","journal-title":"Turk. J. Hematol."},{"key":"54571_CR26","first-page":"4","volume":"10","author":"T Ito","year":"2018","unstructured":"Ito, T. et al. Secondary pure red cell aplasia in multiple myeloma treated with lenalidomide. Leuk. Res. Rep. 10, 4\u20136 (2018).","journal-title":"Leuk. Res. Rep."},{"key":"54571_CR27","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1182\/blood-2010-07-295550","volume":"117","author":"J Flygare","year":"2011","unstructured":"Flygare, J., Estrada, V. R., Shin, C., Gupta, S. & Lodish, H. F. HIF1\u03b1 synergizes with glucocorticoids to promote BFU-E progenitor self-renewal. Blood 117, 3435\u20133444 (2011).","journal-title":"Blood"},{"key":"54571_CR28","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s12185-022-03310-2","volume":"115","author":"F Kawakami","year":"2022","unstructured":"Kawakami, F. et al. T cell clonal expansion and STAT3 mutations: a characteristic feature of acquired chronic T cell-mediated pure red cell aplasia. Int. J. Hematol. 115, 816\u2013825 (2022).","journal-title":"Int. J. Hematol."},{"key":"54571_CR29","first-page":"Ecr47","volume":"91","author":"N Fujishima","year":"2006","unstructured":"Fujishima, N. et al. Oligoclonal T cell expansion in blood but not in the thymus from a patient with thymoma-associated pure red cell aplasia. Haematologica 91, Ecr47 (2006).","journal-title":"Haematologica"},{"key":"54571_CR30","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/ajh.20374","volume":"79","author":"M Masuda","year":"2005","unstructured":"Masuda, M. et al. Clonal T cells of pure red-cell aplasia. Am. J. Hematol. 79, 332\u2013333 (2005).","journal-title":"Am. J. Hematol."},{"key":"54571_CR31","first-page":"341","volume":"9","author":"X Jin","year":"2023","unstructured":"Jin, X. et al. Pure red cell aplasia and minimal residual disease conversion associated with immune reconstitution in a patient with high risk multiple myeloma. Chronic Dis. Transl. Med. 9, 341\u2013344 (2023).","journal-title":"Chronic Dis. Transl. Med."},{"key":"54571_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.molimm.2017.12.005","volume":"113","author":"MLM Jongsma","year":"2019","unstructured":"Jongsma, M. L. M., Guarda, G. & Spaapen, R. M. The regulatory network behind MHC class I expression. Mol. Immunol. 113, 16\u201321 (2019).","journal-title":"Mol. Immunol."},{"key":"54571_CR33","doi-asserted-by":"crossref","unstructured":"Kotsias, F., Cebrian, I., Alloatti, A. Antigen processing and presentation. In: Immunobiology of Dendritic Cells Part A) (2019).","DOI":"10.1016\/bs.ircmb.2019.07.005"},{"key":"54571_CR34","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nri3084","volume":"11","author":"J Neefjes","year":"2011","unstructured":"Neefjes, J., Jongsma, M. L. M., Paul, P. & Bakke, O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol. 11, 823\u2013836 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"54571_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35264-8","volume":"14","author":"J-S Moon","year":"2023","unstructured":"Moon, J.-S. et al. Cytotoxic CD8\u2009+\u2009T cells target citrullinated antigens in rheumatoid arthritis. Nat. Commun. 14, 319 (2023).","journal-title":"Nat. Commun."},{"key":"54571_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.imlet.2012.12.006","volume":"150","author":"Y Michishita","year":"2013","unstructured":"Michishita, Y. et al. CDR3-independent expansion of V\u03b41 T lymphocytes in acquired chronic pure red cell aplasia. Immunol. Lett. 150, 23\u201329 (2013).","journal-title":"Immunol. Lett."},{"key":"54571_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-33928-z","volume":"13","author":"S Park","year":"2023","unstructured":"Park, S. et al. Distinct mutational pattern of T-cell large granular lymphocyte leukemia combined with pure red cell aplasia: low mutational burden of STAT3. Sci. Rep. 13, 7280 (2023).","journal-title":"Sci. Rep."},{"key":"54571_CR38","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1056\/NEJM199705083361906","volume":"336","author":"NS Young","year":"1997","unstructured":"Young, N. S., Epstein, F. H. & Maciejewski, J. The pathophysiology of acquired aplastic anemia. N. Engl. J. Med. 336, 1365\u20131372 (1997).","journal-title":"N. Engl. J. Med."},{"key":"54571_CR39","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","volume":"66","author":"J Liu","year":"1991","unstructured":"Liu, J. et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66, 807\u2013815 (1991).","journal-title":"Cell"},{"key":"54571_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/ki.1996.285","volume":"50","author":"Y Frishberg","year":"1996","unstructured":"Frishberg, Y., Meyers, C. M. & Kelly, C. J. Cyclosporine A regulates T cell-epithelial cell adhesion by altering LFA-1 and ICAM-1 expression. Kidney Int. 50, 45\u201353 (1996).","journal-title":"Kidney Int."},{"key":"54571_CR41","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/339625a0","volume":"339","author":"Y Shi","year":"1989","unstructured":"Shi, Y., Sahai, B. M. & Green, D. R. Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes. Nature 339, 625\u2013626 (1989).","journal-title":"Nature"},{"key":"54571_CR42","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1182\/blood-2012-05-432906","volume":"121","author":"AM de Bruin","year":"2013","unstructured":"De Bruin, A. M., Demirel, \u00d6., Hooibrink, B., Brandts, C. H. & Nolte, M. A. Interferon-\u03b3 impairs proliferation of hematopoietic stem cells in mice. Blood 121, 3578\u20133585 (2013).","journal-title":"Blood"},{"key":"54571_CR43","doi-asserted-by":"publisher","first-page":"752","DOI":"10.4049\/jimmunol.174.2.752","volume":"174","author":"L Yang","year":"2005","unstructured":"Yang, L. et al. IFN-\u03b3 negatively modulates self-renewal of repopulating human hemopoietic stem cells. J. Immunol. 174, 752\u2013757 (2005).","journal-title":"J. Immunol."},{"key":"54571_CR44","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/jcp.1041620116","volume":"162","author":"CQ Wang","year":"1995","unstructured":"Wang, C. Q., Udupa, K. B. & Lipschitz, D. A. Interferon-\u03b3 exerts its negative regulatory effect primarily on the earliest stages of murine erythroid progenitor cell development. J. Cell. Physiol. 162, 134\u2013138 (1995).","journal-title":"J. Cell. Physiol."},{"key":"54571_CR45","doi-asserted-by":"publisher","first-page":"D881","DOI":"10.1093\/nar\/gky1076","volume":"47","author":"FO Bagger","year":"2019","unstructured":"Bagger, F. O., Kinalis, S. & Rapin, N. BloodSpot: a database of healthy and malignant haematopoiesis updated with purified and single cell mRNA sequencing profiles. Nucleic Acids Res. 47, D881\u2013D885 (2019).","journal-title":"Nucleic Acids Res."},{"key":"54571_CR46","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1016\/j.celrep.2019.05.046","volume":"27","author":"LS Ludwig","year":"2019","unstructured":"Ludwig, L. S. et al. Transcriptional states and chromatin accessibility underlying human erythropoiesis. Cell Rep. 27, 3228\u20133240.e3227 (2019).","journal-title":"Cell Rep."},{"key":"54571_CR47","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.4049\/jimmunol.144.3.1069","volume":"144","author":"JM Vinetz","year":"1990","unstructured":"Vinetz, J. M. et al. Adoptive transfer of CD8\u2009+\u2009T cells from immune animals does not transfer immunity to blood stage Plasmodium yoelii malaria. J. Immunol. 144, 1069\u20131074 (1990).","journal-title":"J. Immunol."},{"key":"54571_CR48","doi-asserted-by":"publisher","first-page":"e04232","DOI":"10.7554\/eLife.04232","volume":"4","author":"T Imai","year":"2015","unstructured":"Imai, T. et al. Cytotoxic activities of CD8+ T cells collaborate with macrophages to protect against blood-stage murine malaria. Elife 4, e04232 (2015).","journal-title":"Elife"},{"key":"54571_CR49","first-page":"368","volume":"69","author":"CM Giles","year":"1987","unstructured":"Giles, C. M., Walport, M. J., David, J. & Darke, C. Expression of MHC class I determinants on erythrocytes of SLE patients. Clin. Exp. Immunol. 69, 368\u2013374 (1987).","journal-title":"Clin. Exp. Immunol."},{"key":"54571_CR50","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nature11147","volume":"486","author":"PT Illing","year":"2012","unstructured":"Illing, P. T. et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 486, 554\u2013558 (2012).","journal-title":"Nature"},{"key":"54571_CR51","doi-asserted-by":"publisher","first-page":"F21","DOI":"10.1097\/QAD.0b013e328355fe8f","volume":"26","author":"MA Norcross","year":"2012","unstructured":"Norcross, M. A. et al. Abacavir induces loading of novel self-peptides into HLA-B*57. Aids 26, F21\u2013F29 (2012).","journal-title":"Aids"},{"key":"54571_CR52","doi-asserted-by":"publisher","first-page":"9959","DOI":"10.1073\/pnas.1207934109","volume":"109","author":"DA Ostrov","year":"2012","unstructured":"Ostrov, D. A. et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc. Natl Acad. Sci. USA 109, 9959\u20139964 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"54571_CR53","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3390\/biom11101398","volume":"11","author":"Y Huang","year":"2021","unstructured":"Huang, Y., Wang, H.-C., Zhao, J., Wu, M.-H. & Shih, T.-C. Immunosuppressive roles of galectin-1 in the tumor microenvironment. Biomolecules 11, 1398 (2021).","journal-title":"Biomolecules"},{"key":"54571_CR54","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1084\/jem.194.5.657","volume":"194","author":"JP Medema","year":"2001","unstructured":"Medema, J. P. et al. Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte\u2013induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J. Exp. Med. 194, 657\u2013668 (2001).","journal-title":"J. Exp. Med."},{"key":"54571_CR55","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/BS9.0000000000000109","volume":"4","author":"T Yang","year":"2022","unstructured":"Yang, T., Qian, Y., Liang, X., Wu, J., Zou, M., & Deng, M. LILRB4, an immune checkpoint on myeloid cells. Blood Sci. 4, 49\u201356 (2022).","journal-title":"Blood Sci."},{"key":"54571_CR56","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.cell.2020.10.045","volume":"183","author":"L Jiang","year":"2020","unstructured":"Jiang, L. et al. Direct tumor killing and immunotherapy through anti-SerpinB9 therapy. Cell 183, 1219\u20131233.e1218 (2020).","journal-title":"Cell"},{"key":"54571_CR57","doi-asserted-by":"publisher","unstructured":"Wang, Y. et al. iTALK: an R Package to Characterize and Illustrate Intercellular Communication. bioRxiv https:\/\/doi.org\/10.1101\/507871 (2019).","DOI":"10.1101\/507871"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54571-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54571-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54571-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T08:04:29Z","timestamp":1732262669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54571-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["54571"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-54571-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]},"assertion":[{"value":"26 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10131"}}